Results
Revise Search
Chalk River National Research Universal reactor
https://policybase.cma.ca/en/permalink/policy9919
- Last Reviewed
- 2017-03-04
- Date
- 2010-08-25
- Topics
- Health systems, system funding and performance
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC10-102
- The Canadian Medical Association urges the federal government to make a public commitment to keep the Chalk River National Research Universal reactor operational for as long as necessary beyond the announced date of 2016 and until secure alternative supplies of isotopes or alternative radiopharmaceuticals are proven and available.
- Policy Type
- Policy resolution
- Last Reviewed
- 2017-03-04
- Date
- 2010-08-25
- Topics
- Health systems, system funding and performance
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC10-102
- The Canadian Medical Association urges the federal government to make a public commitment to keep the Chalk River National Research Universal reactor operational for as long as necessary beyond the announced date of 2016 and until secure alternative supplies of isotopes or alternative radiopharmaceuticals are proven and available.
Catastrophic prescription drug program
https://policybase.cma.ca/en/permalink/policy8841
- Last Reviewed
- 2014-03-01
- Date
- 2007-08-22
- Topics
- Health systems, system funding and performance
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC07-11
- The Canadian Medical Association urges the Canadian Institute for Health Information and Statistics Canada to conduct a detailed study of the socio-economic profile of Canadians who have out-of-pocket prescription drug expenses to assess barriers to access and to design strategies that could be built into a catastrophic prescription drug program.
- Policy Type
- Policy resolution
- Last Reviewed
- 2014-03-01
- Date
- 2007-08-22
- Topics
- Health systems, system funding and performance
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC07-11
- The Canadian Medical Association urges the Canadian Institute for Health Information and Statistics Canada to conduct a detailed study of the socio-economic profile of Canadians who have out-of-pocket prescription drug expenses to assess barriers to access and to design strategies that could be built into a catastrophic prescription drug program.
Public prescription drug insurance plans
https://policybase.cma.ca/en/permalink/policy8852
- Last Reviewed
- 2014-03-01
- Date
- 2007-08-22
- Topics
- Health systems, system funding and performance
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC07-22
- The Canadian Medical Association calls on the federal government to provide adequate financial compensation to the provincial and territorial governments that have developed, implemented and funded their own public prescription drug insurance plans.
- Policy Type
- Policy resolution
- Last Reviewed
- 2014-03-01
- Date
- 2007-08-22
- Topics
- Health systems, system funding and performance
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC07-22
- The Canadian Medical Association calls on the federal government to provide adequate financial compensation to the provincial and territorial governments that have developed, implemented and funded their own public prescription drug insurance plans.
Inclusion of expensive drugs
https://policybase.cma.ca/en/permalink/policy8854
- Last Reviewed
- 2014-03-01
- Date
- 2007-08-22
- Topics
- Health systems, system funding and performance
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC07-24
- The Canadian Medical Association urges the federal government to assess the options for risk pooling to cover the inclusion of expensive drugs in public and private drug plan formularies.
- Policy Type
- Policy resolution
- Last Reviewed
- 2014-03-01
- Date
- 2007-08-22
- Topics
- Health systems, system funding and performance
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC07-24
- The Canadian Medical Association urges the federal government to assess the options for risk pooling to cover the inclusion of expensive drugs in public and private drug plan formularies.
Expanding the public plan coverage of health services
https://policybase.cma.ca/en/permalink/policy8855
- Last Reviewed
- 2014-03-01
- Date
- 2007-08-22
- Topics
- Health systems, system funding and performance
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC07-25
- The Canadian Medical Association believes that any request for expanding the public plan coverage of health services, in particular for home care services and the cost of prescription drugs, must include a comprehensive analysis of the potential sources of financing for this expansion.
- Policy Type
- Policy resolution
- Last Reviewed
- 2014-03-01
- Date
- 2007-08-22
- Topics
- Health systems, system funding and performance
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC07-25
- The Canadian Medical Association believes that any request for expanding the public plan coverage of health services, in particular for home care services and the cost of prescription drugs, must include a comprehensive analysis of the potential sources of financing for this expansion.
Delegated professional prescribing
https://policybase.cma.ca/en/permalink/policy8865
- Last Reviewed
- 2014-03-01
- Date
- 2007-08-22
- Topics
- Health systems, system funding and performance
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC07-35
- The Canadian Medical Association affirms that within a multidisciplinary practice delegated professional prescribing is only acceptable when led by a physician clinical leader with ultimate responsibility for patient care.
- Policy Type
- Policy resolution
- Last Reviewed
- 2014-03-01
- Date
- 2007-08-22
- Topics
- Health systems, system funding and performance
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC07-35
- The Canadian Medical Association affirms that within a multidisciplinary practice delegated professional prescribing is only acceptable when led by a physician clinical leader with ultimate responsibility for patient care.
High cost of drugs
https://policybase.cma.ca/en/permalink/policy8906
- Last Reviewed
- 2014-03-01
- Date
- 2007-08-22
- Topics
- Health systems, system funding and performance
- Health care and patient safety
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC07-92
- The Canadian Medical Association urges governments to take prompt measures to address the high cost of generic and off-patent prescription drugs in Canada.
- Policy Type
- Policy resolution
- Last Reviewed
- 2014-03-01
- Date
- 2007-08-22
- Topics
- Health systems, system funding and performance
- Health care and patient safety
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Resolution
- GC07-92
- The Canadian Medical Association urges governments to take prompt measures to address the high cost of generic and off-patent prescription drugs in Canada.
Counterfeit Drugs
https://policybase.cma.ca/en/permalink/policy9068
- Last Reviewed
- 2020-02-29
- Date
- 2007-12-01
- Topics
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Health systems, system funding and performance
- Resolution
- BD08-03-31
- The Canadian Medical Association calls on the Government of Canada to: - implement an anti-counterfeit drugs strategy which could include track-and-trace technology, severe penalties for infractions, and an alert network to encourage reporting by health professionals and patients; and - work with other countries and international organizations on a global effort to stop drug counterfeiting.
- Policy Type
- Policy resolution
- Last Reviewed
- 2020-02-29
- Date
- 2007-12-01
- Topics
- Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
- Health systems, system funding and performance
- Resolution
- BD08-03-31
- The Canadian Medical Association calls on the Government of Canada to: - implement an anti-counterfeit drugs strategy which could include track-and-trace technology, severe penalties for infractions, and an alert network to encourage reporting by health professionals and patients; and - work with other countries and international organizations on a global effort to stop drug counterfeiting.